J. Edwards
Plus aucun poste en cours
Fortune : 68 149 $ au 31/03/2024
Profil
J.
Michael Edwards worked as an Auditor at PricewaterhouseCoopers LLP from 1992 to 1995.
He then worked as a Chief Accounting Officer at U.S.
Global Investors, Inc. from 1997 to 1999.
From 2000 to 2001, he worked as an Assistant Controller at ILEX Oncology, Inc. He then worked as a Controller at BioNumerik Pharmaceuticals, Inc. from 2001 to 2006.
From 2006 to 2007, he worked as a Regional Director-Finance & Accounting at Fieldstone Utah Investors LLC.
He also worked as an Executive Vice President at TurboGenix, Inc. and as a Principal at Progress Energy, Inc., Planergy, Inc., and bioAffinity Technologies, Inc. In 2008, he worked as a Chief Financial Officer at Aviation Upgrade Technologies, Inc. and OncoVista, Inc. He then worked as a Chief Financial Officer at OncoVista Innovative Therapies, Inc. from 2008 to 2011 and at CytoBioscience, Inc. He received his undergraduate degree from the University of Texas at San Antonio and his MBA from the McCombs School of Business at the University of Texas at Austin.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 14/04/2023 | 33 737 ( 0,29% ) | 68 149 $ | 31/03/2024 |
Anciens postes connus de J. Edwards
| Sociétés | Poste | Fin |
|---|---|---|
| BIOAFFINITY TECHNOLOGIES, INC. | Director of Finance/CFO | 01/05/2023 |
| Aviation Upgrade Technologies, Inc. | Director of Finance/CFO | 14/01/2008 |
OncoVista, Inc.
 OncoVista, Inc. Electronic Equipment/InstrumentsElectronic Technology OncoVista, Inc. develops cancer treatment technology. The firm provides drug discovery technologies, clinical development and registration strategies solutions. The company was founded in 2004 and is located in San Antonio, TX. | Director of Finance/CFO | 14/01/2008 |
BioNumerik Pharmaceuticals, Inc.
 BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Comptroller/Controller/Auditor | 01/09/2006 |
Formation de J. Edwards
| The University of Texas at Austin | Graduate Degree |
| McCombs School of Business | Masters Business Admin |
| University of Texas at San Antonio | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| U.S. GLOBAL INVESTORS, INC. | Miscellaneous |
| BIOAFFINITY TECHNOLOGIES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
ILEX Oncology, Inc.
 ILEX Oncology, Inc. BiotechnologyHealth Technology ILEX Oncology, Inc. was a drug development company focused predominantly on accelerated development of drugs for the treatment and prevention of cancer. The company used to offer drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary and used to advance a diversified portfolio of anticancer drugs through its ILEX Products subsidiary. It was located in San Antonio, TX. | Health Technology |
Progress Energy, Inc.
 Progress Energy, Inc. Electric UtilitiesUtilities Progress Energy, Inc. is a public utility holding company. It engages in electric utilities and infrastructure activities. The company was founded on August 19, 1999 and is headquartered in Raleigh, NC. | Utilities |
| Aviation Upgrade Technologies, Inc. | Producer Manufacturing |
BioNumerik Pharmaceuticals, Inc.
BioNumerik Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX. | Health Technology |
PricewaterhouseCoopers LLP
 PricewaterhouseCoopers LLP Miscellaneous Commercial ServicesCommercial Services PricewaterhouseCoopers LLC provides assurance, tax and advisory services. Its services include audit and assurance, consulting, deals, human resources, legal, tax, and family business. The firm also offers accountability, risk management, structuring, mergers and acquisitions, and performance and process improvement. The company was founded in 1998 and is headquartered in Buffalo, NY. | Commercial Services |
OncoVista, Inc.
OncoVista, Inc. Electronic Equipment/InstrumentsElectronic Technology OncoVista, Inc. develops cancer treatment technology. The firm provides drug discovery technologies, clinical development and registration strategies solutions. The company was founded in 2004 and is located in San Antonio, TX. | Electronic Technology |
| OncoVista Innovative Therapies, Inc. | |
CytoBioscience, Inc.
 CytoBioscience, Inc. Medical SpecialtiesHealth Technology CytoBioscience, Inc. manufactures medical devices. It creates and manufactures devices that represent a convergence of bioscience, nano science, microchip development, algorithms and engineering. The firm offers CRO services. The company is headquartered in San Antonio, TX. | Health Technology |
